Introduction
Implantable cardiac electronic devices (ICED) comprise permanent pacemakers (PPM), implantable cardioverter defibrillators (ICD) and cardiac resynchronisation therapy (CRT). Implantation rates in the UK are increasing 1 and are set to rise further in the wake of recent guidelines that significantly widen eligibility criteria. 2 However, an unfortunate consequence is the associated increase in ICED infections with attendant morbidity and mortality.
The incidence of ICED infections is increasing in the US 3 and a similar increase in the UK seems inevitable.
ICED infections can be extremely challenging to diagnose and manage, and can involve any combination of the generator pocket, device leads and endocardial structures; the latter associated with particularly high mortality.
Device extraction has a significant risk of serious complications and mortality. 4 Multiple and long hospital attendances are common and attempts to salvage infected devices are frequently unsuccessful. 5 Strategies for preventing and managing ICED infections vary widely and the evidence to guide practice is limited. Until now, the only published guidelines in this difficult area were from the American Heart Association (AHA) in 2010. 6 Society of Echocardiography (BSE) promote a standardised approach to this important and increasing clinical problem. 7 In this article we summarise their key messages.
Epidemiology
The UK incidence of ICED infection is unknown and extrapolating international estimates may be inappropriate due to varying case definitions and measures of incidence. Acknowledging variable follow up periods, the international literature suggests an overall incidence of infection of 0.5-2.2% of implants, with higher incidence for ICD/CRT compared with PPM and redo procedures compared with primary implants. An increasing number of patients receiving ICED have renal impairment, heart failure and diabetes mellitus, which increase the risk of subsequent infection.
The new guidelines 7 recognise the paucity of UK data and recommend prospective collection of infection rates at 6 months, 1 and 2 years (as well as per 1000 device-years) to define the baseline UK incidence of ICED infection against which future data could be compared. Accurate mortality data are needed -current assessments vary widely due to varying definitions, device types and co-morbidities.
Diagnosis
The guidelines categorise ICED infections as early post implantation inflammation, uncomplicated and complicated generator pocket infections, ICED-infective endocarditis (ICED-IE) and ICED lead infections (ICED-LI) ( Table 1) . Pocket infections are characterised by localised cellulitis, swelling, discharge, dehiscence or pain. Wound inflammation occurring soon after implantation ("superficial cellulitis") can be an early sign of pocket infection, but can also be caused by non-infective conditions. The device should be considered infected once the skin is breached due to erosion. Pocket 
Re-implantation and temporary pacing
The need for ICED re-implantation (and its timing) after removal of an infected system depends on the indications for the original implant. Where possible, reimplantation should be delayed until symptoms and signs of local and systemic infection have resolved. An externalised tunneled system is preferable to a temporary pacing wire via central venous access if interim pacing is needed.
Antibiotic therapy
The 
Prevention Operating environment and personnel
The guidelines acknowledge that implanting ICEDs in an operating theatre environment with dedicated laminar airflow is aspirational. Nevertheless, procedures should take place in an appropriately ventilated (at least 15, but ideally 25 air changes/hr), equipped and cleaned room. Implantations should be performed or supervised by experienced operators 9 and particular reference is made to generator changes, which are associated with a higher incidence of ICED infection than primary implants and are often performed by inexperienced trainees without supervision.
Pre-procedure
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